Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS programPUBT·Aug 11 at 07:09 AMIMUX-0.19%
Immunic Q2 net loss widens to $34.1 million; operating expenses rise to $35.3 millionPUBT·Aug 11 at 05:30 AMIMUX-0.19%
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | IMUX Stock NewsStockTitan·Aug 10 at 09:30 PMIMUX-0.19%
Immunic files Form 3 for director Elena Ridloff, reporting no beneficial ownershipPUBT·Aug 10 at 06:00 PMIMUX-0.19%
Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LPMarket Beat·Aug 1 at 02:40 AMIMUX-0.19%
Immunic Updates Corporate Strategy, Highlights Vidofludimus PlansTip Ranks·Jul 15 at 03:05 AMIMUX-0.19%
Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosisPUBT·Jul 14 at 07:19 AMIMUX-0.19%
Immunic to Participate in Investor Conferences in July | IMUX Stock NewsStockTitan·Jul 8 at 09:30 PMIMUX-0.19%RILY-4.56%
